Market news

AC Immune reported positive safety and immunogenicity results from Part 1 of its Phase 2 Parkinson's disease trial for ACI-7104.

All primary endpoints of the study were met, with ACI-7104 shown to be generally safe and well tolerated Strong immunogenicity demonstrated, with 100% response rate after three immunizationsClear antibody penetration into the cerebrospinal fluid (CSF) and signals for target engagement Discussions with FDA regarding future development path planned for early 2027 AC Immune to host webcast & conference call today at 10:00am EDT / 16:00 CEST details below Lausanne, Switzerland, September 23, 2026 –

AC Immune SA (NASDAQ:ACIU) shares gained 3. 9% in premarket trading on Thursday after the clinical-stage biopharmaceutical company reported preliminary Phase 1 results for ACI-19764, its experimental NLRP3 inflammasome inhibitor.

AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764

AC Immune (ACIU) delivered earnings and revenue surprises of +113.64% and +1,812.10%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

AC Immune First Half 2026 Financial and Corporate Update Focused portfolio of wholly-owned programs approach near-term clinical catalysts as partnered programs generate milestone payments Key advances across pipeline, with further near-term clinical results anticipated for H2 2026Phase 2 VacSYn trial of ACI-7104 in Parkinson’s disease supported by a $4 million grant from The Vijay and Marie Goradia Charitable FoundationMorphomer small molecule program targeting intracellular Tau progresses with

AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026 Lausanne, Switzerland, July 7, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announces three presentations at the Alzheimer's Association International Conference® 2026, taking place July 12-15 in London, UK. Across these AAIC presentations, we are showing how AC Immune’s Morphomer®-based small mo